Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01029873 · ClinicalTrials.gov registry record · Phase 1
QUILT-2.008: Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma
A Phase 1 study, sponsored by Altor BioScience.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT01029873 is a Phase 1 study that has completed, run by Altor BioScience. The registered enrollment target is 25 participants.
The verdict
NCT01029873, a Phase 1 study, has completed, sponsored by Altor BioScience.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
This is a Phase Ib/II, open-label, multi-center, competitive enrollment and dose-escalation study of ALT-801 combined with cisplatin. The purpose of this study is to evaluate the safety, determine the Maximum-Tolerated Dose (MTD), and characterize the pharmacokinetic profile of ALT-801 given with cisplatin in patients who are chemotherapy naïve and have metastatic melanoma that is considered surgically incurable. The anti-tumor responses of ALT-801 with cisplatin will also be assessed in this trial.
Interventions
- DRUG Cisplatin
- BIOLOGICAL ALT-801
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2010-02 |
| Est. Completion | 2013-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01029873
The ClinicalTrials.gov registry entry for NCT01029873 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Altor BioScience, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cisplatin is the first listed.
NCT01029873 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01029873 about?
NCT01029873 is a clinical study titled "QUILT-2.008: Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma". This is a Phase Ib/II, open-label, multi-center, competitive enrollment and dose-escalation study of ALT-801 combined with cisplatin. The purpose of this study is to evaluate the safety, determine the Maximum-Tolerated Dose (MTD), and characterize the pharmacokinetic profile of ALT-801 given with ci...
What is the current status of trial NCT01029873?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2010-02. Estimated completion is 2013-09.
What interventions are being tested in trial NCT01029873?
The interventions under investigation include: Cisplatin (DRUG), ALT-801 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01029873?
This trial is sponsored by Altor BioScience, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.